The FDA approved Pfizer's Xeljanz, or tofacitinib, to treat patients with moderate to severe rheumatoid arthritis who can't tolerate methotrexate or for whom it is ineffective. The approval makes Xeljanz the first rheumatoid arthritis drug from a new class of pain treatments known as JAK inhibitors.